布里格替尼在ALK重排非小细胞肺癌及其他恶性肿瘤中的活性和安全性:一项单臂、开放标签、1/2期试验
该研究为单臂、开放标签1/2期试验,纳入137例晚期恶性肿瘤患者(其中79例为ALK重排NSCLC),评估口服布里格替尼的活性和安全性。结果显示,在克唑替尼经治和初治的ALK重排NSCLC患者中观察到客观缓解,且安全性可接受。
要点
- 布里格替尼在克唑替尼经治的ALK重排NSCLC患者中客观缓解率为72%(51/71)。
- 所有8例克唑替尼初治的ALK重排NSCLC患者均达到确认的客观缓解。
- 最常见的3-4级治疗中出现的不良事件为脂肪酶升高(9%)、呼吸困难(6%)和高血压(5%)。
核心结论
- 布里格替尼在克唑替尼经治和初治的ALK重排NSCLC患者中显示出有前景的临床活性,且安全性可接受。
研究设计与样本
- 该研究为正在进行的单臂、开放标签、1/2期试验,从美国和西班牙的9家学术医院或癌症中心招募患者。
- 纳入年龄至少18岁、患有晚期恶性肿瘤(包括ALK重排NSCLC)且对现有治疗难治或无治愈性治疗的患者。
- 1期剂量递增阶段采用标准3+3设计,口服布里格替尼每日总剂量30-300 mg;1期主要终点为确定2期推荐剂量。
- 2期扩展阶段评估三种口服每日一次方案:90 mg、180 mg、以及180 mg(先以90 mg引导7天);另有一例患者接受90 mg每日两次。
- 2期纳入五个队列:队列1为未接受过ALK抑制剂的ALK重排NSCLC,队列2为克唑替尼经治的ALK重排NSCLC,队列3为EGFR T790M阳性且对一种既往EGFR酪氨酸激酶抑制剂耐药的NSCLC,队列4为其他具有布里格替尼靶点异常的癌症,队列5为有活动性、可测量颅内中枢神经系统转移的克唑替尼初治或经治的ALK重排NSCLC;2期主要终点为客观缓解的患者比例。
主要发现
- 2011年9月20日至2014年7月8日期间,共入组137例患者(79例[58%]为ALK重排NSCLC),所有患者均接受治疗。
- 剂量递增期间观察到的剂量限制性毒性包括3级丙氨酸氨基转移酶升高(240 mg每日)和4级呼吸困难(300 mg每日)。
- 队列1中4例患者有4例(100% [95% CI 40-100])达到客观缓解;队列2中42例患者有31例(74% [58-86])达到客观缓解;队列3中1例患者有0例达到客观缓解;队列4中18例患者有3例(17% [4-41])达到客观缓解;队列5中6例患者有5例(83% [36-100])达到客观缓解。
- 71例克唑替尼经治的ALK重排NSCLC患者中,51例(72% [60-82])达到客观缓解,其中44例(62% [50-73])为确认的客观缓解。
- 所有8例克唑替尼初治的ALK重排NSCLC患者均达到确认的客观缓解(100% [63-100]);队列5中6例患者有3例(50% [95% CI 12-88])达到颅内缓解。
关键数值与推荐
- 所有剂量下最常见的3-4级治疗中出现的不良事件为脂肪酶浓度升高(12/137例,9%)、呼吸困难(8例,6%)和高血压(7例,5%)。
- 至少5%患者报告的严重治疗中出现的不良事件(排除肿瘤进展)包括呼吸困难(10例,7%)、肺炎(9例,7%)和缺氧(7例,5%)。
- 16例(12%)患者在治疗期间或末次布里格替尼给药后31天内死亡,其中8例死于肿瘤进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational ALK inhibitor with potent preclinical activity against ALK mutants resistant to crizotinib and other ALK inhibitors. We aimed to assess brigatinib in patients with advanced malignancies, particularly ALK-rearranged NSCLC. METHODS: In this ongoing, single-arm, open-label, phase 1/2 trial, we recruited patients from nine academic hospitals or cancer centres in the USA and Spain. Eligible patients were at least 18 years of age and had advanced malignancies, including ALK-rearranged NSCLC, and disease that was refractory to available therapies or for which no curative treatments existed. In the initial dose-escalation phase 1 stage of the trial, patients received oral brigatinib at total daily doses of 30-300 mg (according to a standard 3 + 3 design). The phase 1 primary endpoint was establishment of the recommended phase 2 dose. In the phase 2 expansion stage, we assessed three oral once-daily regimens: 90 mg, 180 mg, and 180 mg with a 7 day lead-in at 90 mg; one patient received 90 mg twice daily. We enrolled patients in phase 2 into five cohorts: ALK inhibitor-naive ALK-rearranged NSCLC (cohort 1), crizotinib-treated ALK-rearranged NSCLC (cohort 2), EGFRT790M-positive NSCLC and resistance to one previous EGFR tyrosine kinase inhibitor (cohort 3), other cancers with abnormalities in brigatinib targets (cohort 4), and crizotinib-naive or crizotinib-treated ALK-rearranged NSCLC with active, measurable, intracranial CNS metastases (cohort 5). The phase 2 primary endpoint was the proportion of patients with an objective response. Safety and activity of brigatinib were analysed in all patients in both phases of the trial who had received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, number NCT01449461. FINDINGS: Between Sept 20, 2011, and July 8, 2014, we enrolled 137 patients (79 [58%] with ALK-rearranged NSCLC), all of whom were treated. Dose-limiting toxicities observed during dose escalation included grade 3 increased alanine aminotransferase (240 mg daily) and grade 4 dyspnoea (300 mg daily). We initially chose a dose of 180 mg once daily as the recommended phase 2 dose; however, we also assessed two additional regimens (90 mg once daily and 180 mg once daily with a 7 day lead-in at 90 mg) in the phase 2 stage. four (100% [95% CI 40-100]) of four patients in cohort 1 had an objective response, 31 (74% [58-86]) of 42 did in cohort 2, none (of one) did in cohort 3, three (17% [4-41]) of 18 did in cohort 4, and five (83% [36-100]) of six did in cohort 5. 51 (72% [60-82]) of 71 patients with ALK-rearranged NSCLC with previous crizotinib treatment had an objective response (44 [62% (50-73)] had a confirmed objective response). All eight crizotinib-naive patients with ALK-rearranged NSCLC had a confirmed objective response (100% [63-100]). Three (50% [95% CI 12-88]) of six patients in cohort 5 had an intracranial response. The most common grade 3-4 treatment-emergent adverse events across all doses were increased lipase concentration (12 [9%] of 137), dyspnoea (eight [6%]), and hypertension (seven [5%]). Serious treatment-emergent adverse events (excluding neoplasm progression) reported in at least 5% of all patients were dyspnoea (ten [7%]), pneumonia (nine [7%]), and hypoxia (seven [5%]). 16 (12%) patients died during treatment or within 31 days of the last dose of brigatinib, including eight patients who died from neoplasm progression. INTERPRETATION: Brigatinib shows promising clinical activity and has an acceptable safety profile in patients with crizotinib-treated and crizotinib-naive ALK-rearranged NSCLC. These results support its further development as a potential new treatment option for patients with advanced ALK-rearranged NSCLC. A randomised phase 2 trial in patients with crizotinib-resistant ALK-rearranged NSCLC is prospectively assessing the safety and efficacy of two regimens assessed in the phase 2 portion of this trial (90 mg once daily and 180 mg once daily with a 7 day lead-in at 90 mg). FUNDING: ARIAD Pharmaceuticals.
引用
- Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016. PMID: 27836716. doi:10.1016/S1470-2045(16)30392-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。